Market closed
Inhibikase Therapeutics Inc./$IKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Ticker
$IKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
16
Website
IKT Metrics
BasicAdvanced
$147M
-
-$1.16
1.02
-
Price and volume
Market cap
$147M
Beta
1.02
52-week high
$2.58
52-week low
$1.91
Financial strength
Current ratio
26.369
Quick ratio
26.126
Total debt to equity
0.116
Management effectiveness
Return on assets (TTM)
-31.60%
Return on equity (TTM)
-52.00%
Valuation
Price to book
1.44
Price to tangible book (TTM)
1.44
Price to free cash flow (TTM)
-2.446
Growth
Earnings per share change (TTM)
-63.23%
3-year earnings per share growth (CAGR)
-38.01%
IKT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inhibikase Therapeutics Inc. stock?
Inhibikase Therapeutics Inc. (IKT) has a market cap of $147M as of April 05, 2025.
What is the P/E ratio for Inhibikase Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Inhibikase Therapeutics Inc. (IKT) stock is 0 as of April 05, 2025.
Does Inhibikase Therapeutics Inc. stock pay dividends?
No, Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Inhibikase Therapeutics Inc. dividend payment date?
Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Inhibikase Therapeutics Inc.?
Inhibikase Therapeutics Inc. (IKT) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.